Prestige Consumer Healthcare Inc. Reports Second Quarter and First Half Fiscal 2026 Results
- Revenue of $274.1 million in Q2, ahead of outlook
- Diluted EPS of $0.86 in Q2 and Adjusted Diluted EPS of $1.07, versus prior year Q2 Diluted EPS of $1.09
- Repurchased approximately 1.1 million shares opportunistically in Q2
- Fiscal 2026 revenue outlook unchanged; Adjusted Diluted EPS outlook updated to $4.54 to $4.58, high end of previous range
TARRYTOWN, N.Y., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its second quarter and first six months ended September 30, 2025.
“Our second quarter results surpassed our sales and earnings expectations helped primarily by Clear Eyes® supply timing and the timing of certain retailer orders. We remain pleased with the performance of the remainder of our business, where we continue to focus on brand-building behind our diverse portfolio of leading brands and maintaining our leading financial profile. This proven formula continues to generate robust free cash flow, which enabled us to repurchase over one million in shares during the second quarter to further enhance shareholder value,” said Ron Lombardi, Chief Executive Officer of Prestige Consumer Healthcare.
Second Fiscal Quarter Ended September 30, 2025
Reported revenues in the second quarter of fiscal 2026 of $274.1 million decreased 3.4% from $283.8 million in the second quarter of fiscal 2025 and decreased 3.3% excluding the impact of foreign currency. The revenue decline versus the prior year comparable period was primarily driven by lower Ear & Eye Care category sales from limited ability to supply demand for Clear Eyes.
Reported net income for the second quarter of fiscal 2026 totaled $42.2 million and non-GAAP adjusted net income totaled $52.5 million, compared to the prior year second quarter’s net income of $54.4 million. Diluted earnings per share of $0.86 and non-GAAP adjusted diluted earnings per share of $1.07 for the second quarter of fiscal 2026 compared to $1.09 diluted earnings per share in the prior year comparable period.
The adjustment to the second quarter of fiscal 2026 relates to a discrete tax item pertaining to establishing a taxable presence in a new state.
Six Months Ended September 30, 2025
Reported revenues for the first six months of fiscal 2026 totaled $523.6 million and compared to revenues of $550.9 million for the first six months of fiscal 2025. Revenues decreased 5.0% versus the prior year comparable period and 4.8% excluding the impact of foreign currency. The revenue performance for the first six months reflected the anticipated limited ability to supply strong demand for Clear Eyes as well as the Q1 headwind associated with accelerated order timing in Q4 of the prior year.
Reported net income for the first six months of fiscal 2026 totaled $89.7 million versus the prior year comparable period net income of $103.4 million. Non-GAAP adjusted net income for the first six months of fiscal 2026 totaled $99.9 million versus the prior year comparable period’s adjusted net income of $99.4 million. Diluted earnings per share were $1.81 for the first six months of fiscal 2026 compared to $2.06 per share in the prior year comparable period. Non-GAAP adjusted diluted earnings per share of $2.02 for the first six months of fiscal 2026 increased over the prior year comparable period’s adjusted earnings per share of $1.98.
The adjustment to the first six months of fiscal 2026 relates to a discrete tax item pertaining to establishing a taxable presence in a new state. The adjustment to the first six months of fiscal 2025 relates to a discrete tax item in the first quarter pertaining to the release of a reserve for an uncertain tax position due to the statute of limitations expiring.
Free Cash Flow and Balance Sheet
The Company's net cash provided by operating activities for the first six months of fiscal 2026 was $136.5 million, compared to $124.6 million during the prior year comparable period. Non-GAAP free cash flow in the first six months of fiscal 2026 was $133.6 million compared to $121.4 million in the prior year comparable period.
In the second quarter fiscal 2026, the Company opportunistically repurchased approximately 1.1 million shares at a total investment of approximately $75.0 million. For the first six months fiscal 2026, the total shares repurchased were approximately 1.6 million at a total cost of approximately $109.8 million.
The Company's net debt position as of September 30, 2025 was approximately $0.9 billion, resulting in a covenant-defined leverage ratio of 2.4x.
Segment Review
North American OTC Healthcare: Segment revenues of $230.8 million for the second quarter fiscal 2026 decreased compared to the prior year comparable quarter's segment revenues of $239.8 million. The revenue decrease was primarily attributable to lower Eye & Ear Care category sales, driven primarily by limited ability to supply demand for Clear Eyes.
For the first six months of the current fiscal year, reported revenues for the North American OTC segment were $443.3 million, which compared to $472.1 million in the prior year comparable period. The revenue decrease was primarily attributable to lower Eye & Ear Care category sales, driven by limited ability to supply demand for Clear Eyes as well as the expected headwind associated with accelerated order timing in Q4 of the prior year.
International OTC Healthcare: Fiscal second quarter 2026 revenues of $43.4 million compared to $44.0 million reported in the prior year comparable period. The lower revenue performance was driven by lower Eye & Ear Care category sales and the timing of distributor orders.
For the first six months of the current fiscal year, reported revenues for the International OTC Healthcare segment were $80.3 million, an increase of approximately 2% over the prior year comparable period’s revenues of $78.8 million, or an increase of approximately 3% excluding the effects of foreign currency.
Updated Fiscal 2026 Outlook
“Looking ahead, for the full year, we remain committed to rebuilding long-term supply chain capacity in Clear Eyes and expect to close the Pillar5 transaction as planned. We are reaffirming our fiscal 2026 net sales outlook which anticipates eye care supply improvements in second half thanks to these long-term capacity efforts. For profitability, we are now expecting earnings per share at the higher end of our previous range as well as free cash flow of $245 million or more, driven by our strong financial profile and share repurchases executed in the second quarter,” he continued.
“We continue to remain focused on long-term brand-building that drives long-term organic growth, alongside disciplined capital allocation that helps generate superior shareholder value creation over time,” Mr. Lombardi concluded.
| Prior Fiscal 2026 Outlook | Current Fiscal 2026 Outlook | |
| Revenue | $1,100 to $1,115 million | $1,100 to $1,115 million |
| Organic Revenue Growth | Approximate 1.5% to 3.0% decrease | Approximate 1.5% to 3.0% decrease |
| Adjusted Diluted E.P.S. | $4.50 to $4.58 | $4.54 to $4.58 |
| Free Cash Flow | $245 million or more | $245 million or more |
Second Quarter Fiscal 2026 Conference Call, Accompanying Slide Presentation and Replay
The Company will host a conference call to review its second quarter and first half fiscal 2026 results today, November 6, 2025 at 8:30 a.m. ET. The Company provides a live Internet webcast, a slide presentation to accompany the call, as well as an archived replay, all of which can be accessed from the Investor Relations page of the Company's website at http://www.prestigeconsumerhealthcare.com/. To participate in the conference call via phone, participants may register for the call here to receive dial-in details and a unique pin. While not required, it is recommended to join 10 minutes prior to the event start. The slide presentation can be accessed from the Investor Relations page of the Company’s website by clicking on Webcasts and Presentations.
A conference call replay will be available for approximately one week following completion of the live call and can be accessed on the Company’s Investor Relations page.
Non-GAAP and Other Financial Information
In addition to financial results reported in accordance with generally accepted accounting principles (GAAP), we have provided certain non-GAAP financial information in this release to aid investors in understanding the Company's performance. Each non-GAAP financial measure is defined and reconciled to its most closely related GAAP financial measure in the “About Non-GAAP Financial Measures” section at the end of this earnings release.
Note Regarding Forward-Looking Statements
This news release contains "forward-looking statements" within the meaning of the federal securities laws that are intended to qualify for the Safe Harbor from liability established by the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" generally can be identified by the use of forward-looking terminology such as “on track,” "outlook," "may," "will," "would," “believe,” "expect," “look forward,” "anticipate,” “positioned,” or "continue" (or the negative or other derivatives of each of these terms) or similar terminology. The "forward-looking statements" include, without limitation, statements regarding the Company's future operating results including revenues, organic growth, diluted earnings per share, and free cash flow; the Company’s ability to maintain its financial profile; improvements in eye care supply and the impact of acquiring Pillar5 on the supply of eye care products; and the Company’s ability to enhance shareholder value through its brand-building focus and disciplined capital allocation. These statements are based on management's estimates and assumptions with respect to future events and financial performance and are believed to be reasonable, though are inherently uncertain and difficult to predict. Actual results could differ materially from those expected as a result of a variety of factors, including the impact of business and economic conditions, including as a result of evolving U.S. and international tariffs and trade actions, labor shortages, inflation and geopolitical instability, consumer trends, the impact of the Company’s advertising and marketing and new product development initiatives, customer inventory management initiatives, fluctuating foreign exchange rates, competitive pressures, the ability to meet Pillar5 closing conditions, and the ability of the Company’s manufacturing operations and third party manufacturers and logistics providers and suppliers to meet demand for its products and to avoid inflationary cost increases and disruption. A discussion of other factors that could cause results to vary is included in the Company's Annual Report on Form 10-K for the year ended March 31, 2025 and other periodic reports filed with the Securities and Exchange Commission.
About Prestige Consumer Healthcare Inc.
Prestige Consumer Healthcare is a leading consumer healthcare products company with sales throughout the U.S. and Canada, Australia, and in certain other international markets. The Company’s diverse portfolio of brands include Monistat® and Summer’s Eve® women's health products, BC® and Goody's® pain relievers, Clear Eyes® and TheraTears® eye care products, DenTek® specialty oral care products, Dramamine® motion sickness treatments, Fleet® enemas and glycerin suppositories, Chloraseptic® and Luden's® sore throat treatments and drops, Compound W® wart treatments, Little Remedies® pediatric over-the-counter products, Boudreaux’s Butt Paste® diaper rash ointments, Nix® lice treatment, Debrox® earwax remover, Gaviscon® antacid in Canada, and Hydralyte® rehydration products and the Fess® line of nasal and sinus care products in Australia. Visit the Company's website at www.prestigeconsumerhealthcare.com.
|
Prestige Consumer Healthcare Inc. Condensed Consolidated Statements of Income and Comprehensive Income (Unaudited) | ||||||||||||
| Three Months Ended September 30, | Six Months Ended September 30, | |||||||||||
| (In thousands, except per share data) | 2025 | 2024 | 2025 | 2024 | ||||||||
| Total Revenues | $ | 274,114 | $ | 283,785 | $ | 523,644 | $ | 550,927 | ||||
| Cost of Sales | ||||||||||||
| Cost of sales excluding depreciation | 120,043 | 124,041 | 226,758 | 242,738 | ||||||||
| Cost of sales depreciation | 2,492 | 2,362 | 4,976 | 4,785 | ||||||||
| Cost of sales | 122,535 | 126,403 | 231,734 | 247,523 | ||||||||
| Gross profit | 151,579 | 157,382 | 291,910 | 303,404 | ||||||||
| Operating Expenses | ||||||||||||
| Advertising and marketing | 38,701 | 41,409 | 73,638 | 80,774 | ||||||||
| General and administrative | 28,037 | 26,067 | 56,493 | 54,977 | ||||||||
| Depreciation and amortization | 5,171 | 5,567 | 10,353 | 11,268 | ||||||||
| Total operating expenses | 71,909 | 73,043 | 140,484 | 147,019 | ||||||||
| Operating income | 79,670 | 84,339 | 151,426 | 156,385 | ||||||||
| Other expense | ||||||||||||
| Interest expense, net | 10,036 | 12,281 | 20,239 | 25,418 | ||||||||
| Other expense, net | 501 | 395 | 277 | 891 | ||||||||
| Total other expense, net | 10,537 | 12,676 | 20,516 | 26,309 | ||||||||
| Income before income taxes | 69,133 | 71,663 | 130,910 | 130,076 | ||||||||
| Provision for income taxes | 26,922 | 17,286 | 41,233 | 26,631 | ||||||||
| Net income | $ | 42,211 | $ | 54,377 | $ | 89,677 | $ | 103,445 | ||||
| Earnings per share: | ||||||||||||
| Basic | $ | 0.86 | $ | 1.10 | $ | 1.82 | $ | 2.08 | ||||
| Diluted | $ | 0.86 | $ | 1.09 | $ | 1.81 | $ | 2.06 | ||||
| Weighted average shares outstanding: | ||||||||||||
| Basic | 49,025 | 49,652 | 49,249 | 49,768 | ||||||||
| Diluted | 49,264 | 49,998 | 49,547 | 50,132 | ||||||||
| Comprehensive income, net of tax: | ||||||||||||
| Currency translation adjustments | 655 | 4,799 | 6,059 | 7,959 | ||||||||
| Total other comprehensive income | 655 | 4,799 | 6,059 | 7,959 | ||||||||
| Comprehensive income | $ | 42,866 | $ | 59,176 | $ | 95,736 | $ | 111,404 | ||||
|
Prestige Consumer Healthcare Inc. Condensed Consolidated Balance Sheets (Unaudited) | |||||
| (In thousands) | September 30, 2025 | March 31, 2025 | |||
| Assets | |||||
| Current assets | |||||
| Cash and cash equivalents | $ | 119,106 | $ | 97,884 | |
| Accounts receivable, net of allowance of $19,003 and $16,314, respectively | 199,000 | 194,293 | |||
| Inventories | 158,996 | 147,709 | |||
| Prepaid expenses and other current assets | 20,309 | 8,442 | |||
| Total current assets | 497,411 | 448,328 | |||
| Property, plant and equipment, net | 73,100 | 74,548 | |||
| Operating lease right-of-use assets | 25,427 | 28,238 | |||
| Finance lease right-of-use assets, net | 23,416 | 25,056 | |||
| Goodwill | 528,411 | 527,425 | |||
| Intangible assets, net | 2,291,073 | 2,295,350 | |||
| Other long-term assets | 3,442 | 3,273 | |||
| Total Assets | $ | 3,442,280 | $ | 3,402,218 | |
| Liabilities and Stockholders' Equity | |||||
| Current liabilities | |||||
| Accounts payable | 41,924 | 18,925 | |||
| Accrued interest payable | 15,578 | 15,703 | |||
| Operating lease liabilities, current portion | 6,048 | 6,047 | |||
| Finance lease liabilities, current portion | 2,572 | 2,490 | |||
| Other accrued liabilities | 68,482 | 63,458 | |||
| Total current liabilities | 134,604 | 106,623 | |||
| Long-term debt, net | 993,146 | 992,357 | |||
| Deferred income tax liabilities | 444,924 | 419,594 | |||
| Long-term operating lease liabilities, net of current portion | 19,939 | 22,732 | |||
| Long-term finance lease liabilities, net of current portion | 19,319 | 20,624 | |||
| Other long-term liabilities | 5,379 | 5,391 | |||
| Total Liabilities | 1,617,311 | 1,567,321 | |||
| Total Stockholders' Equity | 1,824,969 | 1,834,897 | |||
| Total Liabilities and Stockholders' Equity | $ | 3,442,280 | $ | 3,402,218 | |
| Prestige Consumer Healthcare Inc. Condensed Consolidated Statements of Cash Flows (Unaudited) | |||||||
| Six Months Ended September 30, | |||||||
| (In thousands) | 2025 | 2024 | |||||
| Operating Activities | |||||||
| Net income | $ | 89,677 | $ | 103,445 | |||
| Adjustments to reconcile net income to net cash provided by operating activities: | |||||||
| Depreciation and amortization | 15,329 | 16,053 | |||||
| Loss on disposal of property and equipment | 131 | 83 | |||||
| Deferred and other income taxes | 23,211 | 4,364 | |||||
| Amortization of debt origination costs | 889 | 882 | |||||
| Stock-based compensation costs | 5,449 | 5,559 | |||||
| Non-cash operating lease cost | 3,879 | 3,430 | |||||
| Changes in operating assets and liabilities: | |||||||
| Accounts receivable | (2,580 | ) | 15,191 | ||||
| Inventories | (10,277 | ) | (16,471 | ) | |||
| Prepaid expenses and other current assets | (11,767 | ) | 3,787 | ||||
| Accounts payable | 22,545 | (7,596 | ) | ||||
| Accrued liabilities | 3,923 | 584 | |||||
| Operating lease liabilities | (3,839 | ) | (3,771 | ) | |||
| Other | (71 | ) | (964 | ) | |||
| Net cash provided by operating activities | 136,499 | 124,576 | |||||
| Investing Activities | |||||||
| Purchases of property, plant and equipment | (2,940 | ) | (3,179 | ) | |||
| Other | (1,927 | ) | (978 | ) | |||
| Net cash (used in) investing activities | (4,867 | ) | (4,157 | ) | |||
| Financing Activities | |||||||
| Term loan repayments | — | (75,000 | ) | ||||
| Payments of finance leases | (1,147 | ) | (1,688 | ) | |||
| Proceeds from exercise of stock options | 3,907 | 3,592 | |||||
| Fair value of shares surrendered as payment of tax withholding | (4,216 | ) | (5,832 | ) | |||
| Repurchase of common stock | (109,775 | ) | (37,794 | ) | |||
| Net cash (used in) financing activities | (111,231 | ) | (116,722 | ) | |||
| Effects of exchange rate changes on cash and cash equivalents | 821 | 1,374 | |||||
| Increase in cash and cash equivalents | 21,222 | 5,071 | |||||
| Cash and cash equivalents - beginning of period | 97,884 | 46,469 | |||||
| Cash and cash equivalents - end of period | $ | 119,106 | $ | 51,540 | |||
| Interest paid | $ | 21,879 | $ | 25,551 | |||
| Income taxes paid | $ | 25,088 | $ | 18,691 | |||
| Prestige Consumer Healthcare Inc. Condensed Consolidated Statements of Income Business Segments (Unaudited) | ||||||||
| Three Months Ended September 30, 2025 | ||||||||
| (In thousands) | North American OTC Healthcare | International OTC Healthcare | Consolidated | |||||
| Total segment revenues* | $ | 230,756 | $ | 43,358 | $ | 274,114 | ||
| Cost of sales | 102,348 | 20,187 | 122,535 | |||||
| Gross profit | 128,408 | 23,171 | 151,579 | |||||
| Advertising and marketing | 32,033 | 6,668 | 38,701 | |||||
| Contribution margin | $ | 96,375 | $ | 16,503 | $ | 112,878 | ||
| Other operating expenses | 33,208 | |||||||
| Operating income | $ | 79,670 | ||||||
*Intersegment revenues of $0.6 million were eliminated from the North American OTC Healthcare segment.
| Six Months Ended September 30, 2025 | |||||||||
| (In thousands) | North American OTC Healthcare | International OTC Healthcare | Consolidated | ||||||
| Total segment revenues* | $ | 443,334 | $ | 80,310 | $ | 523,644 | |||
| Cost of sales | 194,526 | 37,208 | 231,734 | ||||||
| Gross profit | 248,808 | 43,102 | 291,910 | ||||||
| Advertising and marketing | 60,987 | 12,651 | 73,638 | ||||||
| Contribution margin | $ | 187,821 | $ | 30,451 | $ | 218,272 | |||
| Other operating expenses | 66,846 | ||||||||
| Operating income | $ | 151,426 | |||||||
*Intersegment revenues of $1.2 million were eliminated from the North American OTC Healthcare segment.
| Three Months Ended September 30, 2024 | ||||||||
| (In thousands) | North American OTC Healthcare | International OTC Healthcare | Consolidated | |||||
| Total segment revenues* | $ | 239,811 | $ | 43,974 | $ | 283,785 | ||
| Cost of sales | 107,782 | 18,621 | 126,403 | |||||
| Gross profit | 132,029 | 25,353 | 157,382 | |||||
| Advertising and marketing | 34,889 | 6,520 | 41,409 | |||||
| Contribution margin | $ | 97,140 | $ | 18,833 | $ | 115,973 | ||
| Other operating expenses | 31,634 | |||||||
| Operating income | $ | 84,339 | ||||||
* Intersegment revenues of $0.9 million were eliminated from the North American OTC Healthcare segment.
| Six Months Ended September 30, 2024 | ||||||||
| (In thousands) | North American OTC Healthcare | International OTC Healthcare | Consolidated | |||||
| Total segment revenues* | $ | 472,127 | $ | 78,800 | $ | 550,927 | ||
| Cost of sales | 213,341 | 34,182 | 247,523 | |||||
| Gross profit | 258,786 | 44,618 | 303,404 | |||||
| Advertising and marketing | 68,642 | 12,132 | 80,774 | |||||
| Contribution margin | $ | 190,144 | $ | 32,486 | $ | 222,630 | ||
| Other operating expenses | 66,245 | |||||||
| Operating income | $ | 156,385 | ||||||
* Intersegment revenues of $1.6 million were eliminated from the North American OTC Healthcare segment.
About Non-GAAP Financial Measures
In addition to financial results reported in accordance with GAAP, we disclose certain Non-GAAP financial measures ("NGFMs"), including, but not limited to, Non-GAAP Organic Revenues, Non-GAAP Organic Revenue Change Percentage, Non-GAAP EBITDA, Non-GAAP EBITDA Margin, Non-GAAP Adjusted Net Income, Non-GAAP Adjusted Diluted EPS, Non-GAAP Free Cash Flow, and Net Debt. We use these NGFMs internally, along with GAAP information, in evaluating our operating performance and in making financial and operational decisions. We believe that the presentation of these NGFMs provides investors with greater transparency, and provides a more complete understanding of our business than could be obtained absent these disclosures, because the supplemental data relating to our financial condition and results of operations provides additional ways to view our operation when considered with both our GAAP results and the reconciliations below. In addition, we believe that the presentation of each of these NGFMs is useful to investors for period-to-period comparisons of results in assessing shareholder value, and we use these NGFMs internally to evaluate the performance of our personnel and also to evaluate our operating performance and compare our performance to that of our competitors.
These NGFMs are not in accordance with GAAP, should not be considered as a measure of profitability or liquidity, and may not be directly comparable to similarly titled NGFMs reported by other companies. These NGFMs have limitations and they should not be considered in isolation from or as an alternative to their most closely related GAAP measures reconciled below. Investors should not rely on any single financial measure when evaluating our business. We recommend investors review the GAAP financial measures included in this earnings release. When viewed in conjunction with our GAAP results and the reconciliations below, we believe these NGFMs provide greater transparency and a more complete understanding of factors affecting our business than GAAP measures alone.
NGFMs Defined
We define our NGFMs presented herein as follows:
- Non-GAAP Organic Revenues: GAAP Total Revenues excluding the impact of foreign currency exchange rates in the periods presented.
- Non-GAAP Organic Revenue Change Percentage: Calculated as the change in Non-GAAP Organic Revenues from prior year divided by prior year Non-GAAP Organic Revenues.
- Non-GAAP EBITDA: GAAP Net Income before interest expense, net, provision for income taxes, and depreciation and amortization.
- Non-GAAP EBITDA Margin: Calculated as Non-GAAP EBITDA divided by GAAP Total Revenues.
- Non-GAAP Adjusted Net Income: GAAP Net Income adjusted for a normalized tax rate.
- Non-GAAP Adjusted Diluted EPS: Calculated as Non-GAAP Adjusted Net Income, divided by the diluted
weighted average number of shares outstanding during the period.
- Non-GAAP Free Cash Flow: Calculated as GAAP Net cash provided by operating activities less cash paid for capital expenditures.
- Net Debt: Calculated as total principal amount of debt outstanding ($1,000,000 at September 30, 2025) less cash and cash equivalents ($119,106 at September 30, 2025). Amounts in thousands.
The following tables set forth the reconciliations of each of our NGFMs (other than Net Debt, which is reconciled above) to their most directly comparable financial measures presented in accordance with GAAP.
Reconciliation of GAAP Total Revenues to Non-GAAP Organic Revenues and related Non-GAAP Organic Revenue Change percentage:
| Three Months Ended September 30, | Six Months Ended September 30, | ||||||||||||
|
2025 |
2024 |
2025 |
2024 | ||||||||||
| (In thousands) | |||||||||||||
| GAAP Total Revenues | $ | 274,114 | $ | 283,785 | $ | 523,644 | $ | 550,927 | |||||
| Revenue Change | (3.4)% | (5.0)% | |||||||||||
| Adjustments: | |||||||||||||
| Impact of foreign currency exchange rates | — | (370 | ) | — | (1,040 | ) | |||||||
| Total adjustments | — | (370 | ) | — | (1,040 | ) | |||||||
| Non-GAAP Organic Revenues | $ | 274,114 | $ | 283,415 | $ | 523,644 | $ | 549,887 | |||||
| Non-GAAP Organic Revenue Change | (3.3)% | (4.8)% | |||||||||||
Reconciliation of GAAP Net Income to Non-GAAP EBITDA and related Non-GAAP EBITDA Margin:
| Three Months Ended September 30, | Six Months Ended September 30, | ||||||||||||||
| 2025 | 2024 | 2025 | 2024 | ||||||||||||
| (In thousands) | |||||||||||||||
| GAAP Net Income | $ | 42,211 | $ | 54,377 | $ | 89,677 | $ | 103,445 | |||||||
| Interest expense, net | 10,036 | 12,281 | 20,239 | 25,418 | |||||||||||
| Provision for income taxes | 26,922 | 17,286 | 41,233 | 26,631 | |||||||||||
| Depreciation and amortization | 7,663 | 7,929 | 15,329 | 16,053 | |||||||||||
| Non-GAAP EBITDA | $ | 86,832 | $ | 91,873 | $ | 166,478 | $ | 171,547 | |||||||
| Non-GAAP EBITDA Margin | 31.7 | % | 32.4 | % | 31.8 | % | 31.1 | % | |||||||
Reconciliation of GAAP Net Income and GAAP Diluted Earnings Per Share to Non-GAAP Adjusted Net Income and related Non-GAAP Adjusted Diluted Earnings Per Share:
| Three Months Ended September 30, | Six Months Ended September 30, | ||||||||||||||||||||
| 2025 | 2025 Diluted EPS | 2024 | 2024 Diluted EPS | 2025 | 2025 Diluted EPS |
2024 |
2024 Diluted EPS | ||||||||||||||
| (In thousands, except per share data) | |||||||||||||||||||||
| GAAP Net Income and Diluted EPS | $ | 42,211 | $ | 0.86 | $ | 54,377 | $ | 1.09 | $ | 89,677 | $ | 1.81 | $ | 103,445 | $ | 2.06 | |||||
| Adjustments: | |||||||||||||||||||||
| Normalized tax rate adjustment(1) | 10,261 | 0.21 | — | — | 10,261 | 0.21 | (4,030 | ) | $ | (0.08 | ) | ||||||||||
| Total adjustments | 10,261 | 0.21 | — | — | 10,261 | 0.21 | (4,030 | ) | (0.08 | ) | |||||||||||
| Non-GAAP Adjusted Net Income and Adjusted Diluted EPS | $ | 52,472 | $ | 1.07 | $ | 54,377 | $ | 1.09 | $ | 99,938 | $ | 2.02 | $ | 99,415 | $ | 1.98 | |||||
(1) Income tax adjustment to adjust for discrete income tax items.
Reconciliation of GAAP Net Income to Non-GAAP Free Cash Flow:
| Three Months Ended September 30, | Six Months Ended September 30, | ||||||||||||||
| 2025 | 2024 | 2025 | 2024 | ||||||||||||
| (In thousands) | |||||||||||||||
| GAAP Net Income | $ | 42,211 | $ | 54,377 | $ | 89,677 | $ | 103,445 | |||||||
| Adjustments: | |||||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities as shown in the Statement of Cash Flows | 29,324 | 16,045 | 48,888 | 30,371 | |||||||||||
| Changes in operating assets and liabilities as shown in the Statement of Cash Flows | (14,049 | ) | (622 | ) | (2,066 | ) | (9,240 | ) | |||||||
| Total adjustments | 15,275 | 15,423 | 46,822 | 21,131 | |||||||||||
| GAAP Net cash provided by operating activities | 57,486 | 69,800 | 136,499 | 124,576 | |||||||||||
| Purchases of property and equipment | (2,102 | ) | (2,027 | ) | (2,940 | ) | (3,179 | ) | |||||||
| Non-GAAP Free Cash Flow | $ | 55,384 | $ | 67,773 | $ | 133,559 | $ | 121,397 | |||||||
Outlook for Fiscal Year 2026:
Reconciliation of Projected GAAP Net cash provided by operating activities to Projected Non-GAAP Free Cash Flow:
| (In millions) | |||
| Projected FY'26 GAAP Net cash provided by operating activities | $ | 255 | |
| Additions to property and equipment for cash | (10 | ) | |
| Projected FY'26 Non-GAAP Free Cash Flow | $ | 245 | |
Reconciliation of Projected GAAP Diluted EPS to Projected Non-GAAP Adjusted Diluted EPS:
| Low | High | ||||
| Projected FY'26 GAAP Diluted EPS | $ | 4.33 | $ | 4.37 | |
| Adjustments: | |||||
| Normalized tax rate adjustment(1) | 0.21 | 0.21 | |||
| Projected FY'26 Non-GAAP Adjusted Diluted EPS | $ | 4.54 | $ | 4.58 | |
(1) Income tax adjustment to adjust for discrete income tax items.
Investor Relations Contact
Phil Terpolilli, CFA, 914-524-6819
irinquiries@prestigebrands.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
